ALNY Alnylam Pharmaceuticals | $401.80
+2.4% | 8/1/2025 | Keay Nakae | Boost Price Target | Buy -> Buy | $325.00 -> $400.00 | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 8/1/2025 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 8/1/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $25.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 8/1/2025 |
MNMD Mind Medicine (MindMed) | $8.44
-7.2% | 8/1/2025 | Rudy Li | Reiterated Rating | Buy -> Buy | $20.00 | View details for Chardan Capital rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 8/1/2025 |
CNTA Centessa Pharmaceuticals | $16.81
-2.1% | 7/30/2025 | Rudy Li | Reiterated Rating | Buy -> Buy | $30.00 | View details for Chardan Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 7/30/2025 |
QURE uniQure | $13.69
-1.7% | 7/29/2025 | Daniil Gataulin | Lower Price Target | Buy -> Buy | $38.00 -> $35.00 | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 7/29/2025 |
DYN Dyne Therapeutics | $10.05
+2.0% | 7/29/2025 | Keay Nakae | Lower Price Target | Buy -> Buy | $50.00 -> $38.00 | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 7/29/2025 |
PRAX Praxis Precision Medicines | $54.09
-0.2% | 7/29/2025 | Rudy Li | Reiterated Rating | Buy -> Buy | $80.00 | View details for Chardan Capital rating of Praxis Precision Medicines (NASDAQ:PRAX) on 7/29/2025 |
KRYS Krystal Biotech | $156.98
+2.0% | 7/25/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $219.00 | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 7/25/2025 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 7/24/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $17.00 -> $12.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 7/24/2025 |
IOVA Iovance Biotherapeutics | $2.68
+4.3% | 7/23/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $25.00 | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 7/23/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
CLSD Clearside Biomedical | $0.38
-7.8% | 7/18/2025 | Daniil Gataulin | Downgrade | Buy -> Neutral | | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 7/18/2025 |
CLSK Cleanspark | $10.44
-8.2% | 7/8/2025 | J. Mcilree | Reiterated Rating | Buy -> Buy | $20.00 | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 7/8/2025 |
VFS VinFast Auto | $3.39
-0.9% | 7/7/2025 | J. Mcilree | Reiterated Rating | Buy -> Buy | $5.50 | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 7/7/2025 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 7/3/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $25.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 7/3/2025 |
COYA Coya Therapeutics | $6.09
+2.4% | 7/1/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 7/1/2025 |
CRSP CRISPR Therapeutics | $56.09
-0.3% | 6/26/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $82.00 | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 6/26/2025 |
IBIO iBio | $0.66
-3.1% | 6/25/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $5.00 | View details for Chardan Capital rating of iBio (NYSE:IBIO) on 6/25/2025 |
CLSK Cleanspark | $10.44
-8.2% | 6/25/2025 | J. Mcilree | Reiterated Rating | Buy -> Buy | $20.00 | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 6/25/2025 |
PASG Passage Bio | $5.74
-10.6% | 6/24/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $120.00 | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 6/24/2025 |
FBRX Forte Biosciences | $9.61
-3.7% | 6/24/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $61.00 | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 6/24/2025 |
OCGN Ocugen | $0.99
-3.5% | 6/24/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $7.00 | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 6/24/2025 |
VFS VinFast Auto | $3.39
-0.9% | 6/23/2025 | J. Mcilree | Reiterated Rating | Buy -> Buy | $5.50 | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 6/23/2025 |
MNPR Monopar Therapeutics | $40.69
-1.2% | 6/23/2025 | Keay Nakae | Initiated Coverage | Buy | $60.00 | View details for Chardan Capital rating of Monopar Therapeutics (NASDAQ:MNPR) on 6/23/2025 |
IMRX Immuneering | $3.37
-2.0% | 6/18/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $13.00 | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 6/18/2025 |
DYN Dyne Therapeutics | $10.05
+2.0% | 6/17/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $50.00 | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 6/17/2025 |
SNTI Senti Biosciences | $1.68
-1.2% | 6/12/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $12.00 | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 6/12/2025 |
VFS VinFast Auto | $3.39
-0.9% | 6/10/2025 | J. Mcilree | Reiterated Rating | Buy -> Buy | $5.50 | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 6/10/2025 |
RNA Avidity Biosciences | $35.92
-2.2% | 6/9/2025 | Keay Nakae | Boost Price Target | Buy -> Buy | $65.00 -> $75.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 6/9/2025 |
RGNX REGENXBIO | $8.19
-3.8% | 6/9/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $52.00 | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 6/9/2025 |
QURE uniQure | $13.69
-1.7% | 5/30/2025 | D. Gataulin | Reiterated Rating | Buy -> Buy | $38.00 | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/30/2025 |
WBX Wallbox | $4.87
-5.9% | 5/28/2025 | J. Mcilree | Upgrade | Hold | | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 5/28/2025 |
TSHA Taysha Gene Therapies | $2.63
-3.7% | 5/29/2025 | Geulah Livshits | Boost Price Target | Buy -> Buy | $7.00 -> $9.00 | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 5/29/2025 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 5/28/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $46.00 -> $17.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/28/2025 |
PRTA Prothena | $6.81
-0.9% | 5/27/2025 | R. Li | Lower Price Target | Buy -> Buy | $40.00 -> $18.00 | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 5/27/2025 |
DRUG Bright Minds Biosciences | $33.63
-0.4% | 5/21/2025 | R. Li | Reiterated Rating | Buy -> Buy | $80.00 -> $80.00 | View details for Chardan Capital rating of Bright Minds Biosciences (NASDAQ:DRUG) on 5/21/2025 |
CLSK Cleanspark | $10.44
-8.2% | 5/21/2025 | J. Mcilree | Initiated Coverage | Buy -> Buy | $26.00 -> $20.00 | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 5/21/2025 |
PRME Prime Medicine | $4.04
+8.0% | 5/19/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $16.00 -> $12.00 | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 5/19/2025 |
SLDB Solid Biosciences | $6.83
-0.1% | 5/19/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $16.00 -> $15.00 | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 5/19/2025 |
IPSC Century Therapeutics | $0.53
-2.9% | 5/16/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $7.00 -> $6.00 | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 5/16/2025 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 5/16/2025 | Geulah Livshits | Boost Price Target | Buy -> Buy | $45.00 -> $46.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/16/2025 |
Trump Did What!? (Ad) Last May, President Trump signed four executive orders that could spark the biggest energy disruption in decades. This move opens the door for a next-gen power source with the potential to upend oil and gas, slash emissions, and accelerate artificial intelligence breakthroughs.
While stocks tied to this trend have already soared, one overlooked corner of the industry could deliver even bigger gains—and it’s still flying under the radar. Get the name and ticker of the breakout stock positioned for this energy revolution. |
SABS SAB Biotherapeutics | $2.23
+18.6% | 5/15/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $20.00 -> $20.00 | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 5/15/2025 |
ADVM Adverum Biotechnologies | $2.32
-2.9% | 5/15/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $33.00 -> $33.00 | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 5/15/2025 |
MGX Metagenomi | $2.25
-2.2% | 5/15/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $13.00 -> $12.00 | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 5/15/2025 |
MGTX MeiraGTx | $7.65
| 5/14/2025 | Daniil Gataulin | Lower Price Target | Buy -> Buy | $38.00 -> $35.00 | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 5/14/2025 |
COYA Coya Therapeutics | $6.09
+2.4% | 5/13/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 5/13/2025 |
KRRO Korro Bio | $13.85
-7.4% | 5/13/2025 | K. Nakae | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of Korro Bio (NASDAQ:KRRO) on 5/13/2025 |
OBIO Orchestra BioMed | $2.44
-20.3% | 5/13/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $20.00 -> $20.00 | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 5/13/2025 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 5/13/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $22.00 -> $20.00 | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 5/13/2025 |
ARWR Arrowhead Pharmaceuticals | $15.93
+0.8% | 5/13/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $60.00 -> $60.00 | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/13/2025 |
XENE Xenon Pharmaceuticals | $30.50
-0.1% | 5/13/2025 | R. Li | Reiterated Rating | Buy -> Buy | $55.00 -> $55.00 | View details for Chardan Capital rating of Xenon Pharmaceuticals (NASDAQ:XENE) on 5/13/2025 |
CRVO CervoMed | $8.83
+7.0% | 5/12/2025 | D. Gataulin | Boost Price Target | Buy -> Buy | $14.00 -> $15.00 | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 5/12/2025 |
QURE uniQure | $13.69
-1.7% | 5/12/2025 | D. Gataulin | Reiterated Rating | Buy -> Buy | $38.00 -> $38.00 | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/12/2025 |
OCGN Ocugen | $0.99
-3.5% | 5/12/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $7.00 -> $7.00 | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 5/12/2025 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 5/9/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $28.00 -> $25.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 5/9/2025 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 5/9/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $54.00 -> $45.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/9/2025 |
IOVA Iovance Biotherapeutics | $2.68
+4.3% | 5/9/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $30.00 -> $25.00 | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/9/2025 |
OCS Oculis | $17.70
+0.3% | 5/9/2025 | Daniil Gataulin | Boost Price Target | Buy -> Buy | $28.00 -> $33.00 | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 5/9/2025 |
DYN Dyne Therapeutics | $10.05
+2.0% | 5/9/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $50.00 -> $50.00 | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 5/9/2025 |
PRTA Prothena | $6.81
-0.9% | 5/9/2025 | R. Li | Reiterated Rating | Buy -> Buy | $40.00 -> $40.00 | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 5/9/2025 |
TNYA Tenaya Therapeutics | $0.67
-0.8% | 5/9/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $9.00 -> $9.00 | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 5/9/2025 |
NTLA Intellia Therapeutics | $11.49
-1.3% | 5/9/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $68.00 -> $68.00 | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 5/9/2025 |
MNMD Mind Medicine (MindMed) | $8.44
-7.2% | 5/9/2025 | R. Li | Reiterated Rating | Buy -> Buy | $20.00 -> $20.00 | View details for Chardan Capital rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 5/9/2025 |
EYPT EYEPOINT PHARMACEUTICALS | $9.71
-1.1% | 5/8/2025 | Daniil Gataulin | Lower Price Target | Buy -> Buy | $33.00 -> $27.00 | View details for Chardan Capital rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 5/8/2025 |
CGTX Cognition Therapeutics | $0.67
+13.9% | 5/8/2025 | Daniil Gataulin | Lower Price Target | Buy -> Buy | $8.00 -> $4.00 | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 5/8/2025 |
MCRB Seres Therapeutics | $13.99
-1.9% | 5/8/2025 | Keay Nakae | Reiterated Rating | Buy -> Neutral | $1.25 -> $6.00 | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 5/8/2025 |
CNTA Centessa Pharmaceuticals | $16.81
-2.1% | 5/8/2025 | Rudy Li | Initiated Coverage | Buy | $30.00 | View details for Chardan Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 5/8/2025 |
DRUG Bright Minds Biosciences | $33.63
-0.4% | 5/7/2025 | Rudy Li | Initiated Coverage | Buy | $80.00 | View details for Chardan Capital rating of Bright Minds Biosciences (NASDAQ:DRUG) on 5/7/2025 |
PRAX Praxis Precision Medicines | $54.09
-0.2% | 5/7/2025 | Rudy Li | Initiated Coverage | Buy | $80.00 | View details for Chardan Capital rating of Praxis Precision Medicines (NASDAQ:PRAX) on 5/7/2025 |
CRSP CRISPR Therapeutics | $56.09
-0.3% | 5/7/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $84.00 -> $82.00 | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 5/7/2025 |
XENE Xenon Pharmaceuticals | $30.50
-0.1% | 5/7/2025 | Rudy Li | Initiated Coverage | Buy | $55.00 | View details for Chardan Capital rating of Xenon Pharmaceuticals (NASDAQ:XENE) on 5/7/2025 |
RNA Avidity Biosciences | $35.92
-2.2% | 5/7/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $65.00 -> $65.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 5/7/2025 |
KRYS Krystal Biotech | $156.98
+2.0% | 5/7/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $219.00 -> $219.00 | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 5/7/2025 |
IMRX Immuneering | $3.37
-2.0% | 5/6/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $13.00 -> $13.00 | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 5/6/2025 |
QURE uniQure | $13.69
-1.7% | 5/6/2025 | D. Gataulin | Reiterated Rating | Buy -> Buy | $38.00 -> $38.00 | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/6/2025 |
IBIO iBio | $0.66
-3.1% | 5/5/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $5.00 -> $5.00 | View details for Chardan Capital rating of iBio (NYSE:IBIO) on 5/5/2025 |
TRML Tourmaline Bio | $21.76
-1.7% | 5/5/2025 | D. Gataulin | Reiterated Rating | Buy -> Buy | $70.00 -> $70.00 | View details for Chardan Capital rating of Tourmaline Bio (NASDAQ:TRML) on 5/5/2025 |
SNTI Senti Biosciences | $1.68
-1.2% | 5/2/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $12.00 -> $12.00 | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 5/2/2025 |
ALNY Alnylam Pharmaceuticals | $401.80
+2.4% | 5/2/2025 | Keay Nakae | Boost Price Target | Buy -> Buy | $300.00 -> $325.00 | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 5/2/2025 |
WBX Wallbox | $4.87
-5.9% | 4/29/2025 | J. Mcilree | Upgrade | Hold | | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 4/29/2025 |
VFS VinFast Auto | $3.39
-0.9% | 4/29/2025 | J. Mcilree | Upgrade | Strong-Buy | | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 4/29/2025 |
CLSK Cleanspark | $10.44
-8.2% | 4/29/2025 | J. Mcilree | Upgrade | Strong-Buy | | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 4/29/2025 |
COYA Coya Therapeutics | $6.09
+2.4% | 4/28/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 4/28/2025 |
VFS VinFast Auto | $3.39
-0.9% | 4/28/2025 | K. Nakae | Reiterated Rating | Buy | $13.00 -> $5.50 | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 4/28/2025 |
TRML Tourmaline Bio | $21.76
-1.7% | 4/23/2025 | Daniil Gataulin | Initiated Coverage | Buy | $70.00 | View details for Chardan Capital rating of Tourmaline Bio (NASDAQ:TRML) on 4/23/2025 |
OBIO Orchestra BioMed | $2.44
-20.3% | 4/22/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $20.00 -> $20.00 | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 4/22/2025 |
OCS Oculis | $17.70
+0.3% | 4/17/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $28.00 -> $28.00 | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 4/17/2025 |
ADVM Adverum Biotechnologies | $2.32
-2.9% | 4/17/2025 | Daniil Gataulin | Lower Price Target | Buy -> Buy | $40.00 -> $33.00 | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/17/2025 |
KRRO Korro Bio | $13.85
-7.4% | 4/16/2025 | Keay Nakae | Initiated Coverage | Buy | $25.00 | View details for Chardan Capital rating of Korro Bio (NASDAQ:KRRO) on 4/16/2025 |
PVLA Palvella Therapeutics | $36.55
-0.1% | 4/9/2025 | Geulah Livshits | Initiated Coverage | Buy | $50.00 | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 4/9/2025 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 4/8/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $25.00 -> $22.00 | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 4/8/2025 |
The Coin That Could Define Trump’s Crypto Presidency (Ad) When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed.
While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.” Discover the coin that could define Trump’s crypto presidency. |
OBIO Orchestra BioMed | $2.44
-20.3% | 4/1/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $20.00 -> $20.00 | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 4/1/2025 |
FBRX Forte Biosciences | $9.61
-3.7% | 4/1/2025 | Daniil Gataulin | Lower Price Target | Buy -> Buy | $64.00 -> $61.00 | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 4/1/2025 |
SABS SAB Biotherapeutics | $2.23
+18.6% | 4/1/2025 | Keay Nakae | Lower Price Target | Buy -> Buy | $25.00 -> $20.00 | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 4/1/2025 |
QURE uniQure | $13.69
-1.7% | 4/1/2025 | Daniil Gataulin | Initiated Coverage | Buy -> Buy | $27.00 -> $38.00 | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 4/1/2025 |
CLSD Clearside Biomedical | $0.38
-7.8% | 3/28/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 3/28/2025 |
ABUS Arbutus Biopharma | $3.27
-0.3% | 3/28/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $5.00 -> $5.00 | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 3/28/2025 |
GANX Gain Therapeutics | $1.44
-1.4% | 3/28/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 3/28/2025 |
ALUR Allurion Technologies | $2.76
-0.7% | 3/27/2025 | K. Nakae | Reiterated Rating | Neutral -> Neutral | $2.50 -> $2.50 | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 3/27/2025 |
ZURA Zura Bio | $1.50
+7.1% | 3/26/2025 | Matthew Barcus | Lower Price Target | Buy -> Buy | $12.00 -> $10.00 | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 3/26/2025 |
WBX Wallbox | $4.87
-5.9% | 3/24/2025 | K. Nakae | Upgrade | Hold | | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 3/24/2025 |
VFS VinFast Auto | $3.39
-0.9% | 3/24/2025 | K. Nakae | Upgrade | Strong-Buy | | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 3/24/2025 |
CLSK Cleanspark | $10.44
-8.2% | 3/24/2025 | K. Nakae | Upgrade | Strong-Buy | | View details for Chardan Capital rating of Cleanspark (NASDAQ:CLSK) on 3/24/2025 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 3/25/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 3/25/2025 |
IMRX Immuneering | $3.37
-2.0% | 3/24/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $13.00 -> $13.00 | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 3/24/2025 |
IPSC Century Therapeutics | $0.53
-2.9% | 3/24/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $11.00 -> $7.00 | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 3/24/2025 |
ALNY Alnylam Pharmaceuticals | $401.80
+2.4% | 3/21/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $300.00 -> $300.00 | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 3/21/2025 |
ALUR Allurion Technologies | $2.76
-0.7% | 3/21/2025 | K. Nakae | Reiterated Rating | Neutral -> Neutral | $2.50 | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 3/21/2025 |
CGTX Cognition Therapeutics | $0.67
+13.9% | 3/21/2025 | Daniil Gataulin | Lower Price Target | Buy -> Buy | $11.00 -> $8.00 | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 3/21/2025 |
MCRB Seres Therapeutics | $13.99
-1.9% | 3/20/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 3/20/2025 |
RGNX REGENXBIO | $8.19
-3.8% | 3/20/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $52.00 -> $52.00 | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 3/20/2025 |
PRME Prime Medicine | $4.04
+8.0% | 3/20/2025 | Geulah Livshits | Boost Price Target | Buy -> Buy | $15.00 -> $16.00 | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 3/20/2025 |
COYA Coya Therapeutics | $6.09
+2.4% | 3/20/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/20/2025 |
STOK Stoke Therapeutics | $12.91
+0.5% | 3/19/2025 | R. Li | Reiterated Rating | Buy -> Buy | $24.00 -> $24.00 | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 3/19/2025 |
RNA Avidity Biosciences | $35.92
-2.2% | 3/17/2025 | K. Nakae | Reiterated Rating | Buy -> Buy | $65.00 -> $65.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 3/17/2025 |
DYN Dyne Therapeutics | $10.05
+2.0% | 3/17/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $50.00 -> $50.00 | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/17/2025 |
PRQR ProQR Therapeutics | $2.08
-1.0% | 3/14/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $4.00 -> $4.00 | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 3/14/2025 |
RGNX REGENXBIO | $8.19
-3.8% | 3/14/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $52.00 -> $52.00 | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 3/14/2025 |
OCS Oculis | $17.70
+0.3% | 3/13/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $28.00 -> $28.00 | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 3/13/2025 |
CRVO CervoMed | $8.83
+7.0% | 3/13/2025 | D. Gataulin | Upgrade | Neutral -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/13/2025 |
TNYA Tenaya Therapeutics | $0.67
-0.8% | 3/12/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $18.00 -> $9.00 | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/12/2025 |
SLDB Solid Biosciences | $6.83
-0.1% | 3/7/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $16.00 -> $16.00 | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/7/2025 |
EYPT EYEPOINT PHARMACEUTICALS | $9.71
-1.1% | 3/6/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $33.00 -> $33.00 | View details for Chardan Capital rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 3/6/2025 |
OCGN Ocugen | $0.99
-3.5% | 3/6/2025 | Daniil Gataulin | Boost Price Target | Buy -> Buy | $6.00 -> $7.00 | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/6/2025 |
PASG Passage Bio | $5.74
-10.6% | 3/4/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $140.00 -> $120.00 | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 3/4/2025 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 3/4/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $30.00 -> $28.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 3/4/2025 |
PRME Prime Medicine | $4.04
+8.0% | 3/3/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $15.00 -> $15.00 | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 3/3/2025 |
IOVA Iovance Biotherapeutics | $2.68
+4.3% | 3/3/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $34.00 -> $30.00 | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 3/3/2025 |
NTLA Intellia Therapeutics | $11.49
-1.3% | 2/28/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $91.00 -> $68.00 | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/28/2025 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 2/28/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $62.00 -> $54.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 2/28/2025 |
DYN Dyne Therapeutics | $10.05
+2.0% | 2/28/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $50.00 -> $50.00 | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 2/28/2025 |
RNA Avidity Biosciences | $35.92
-2.2% | 2/28/2025 | K. Nakae | Reiterated Rating | Buy -> Buy | $65.00 -> $65.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 2/28/2025 |
CGTX Cognition Therapeutics | $0.67
+13.9% | 2/26/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $11.00 -> $11.00 | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 2/26/2025 |
TSHA Taysha Gene Therapies | $2.63
-3.7% | 2/26/2025 | Geulah Livshits | Reiterated Rating | Buy -> Buy | $7.00 -> $7.00 | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 2/26/2025 |
ALNY Alnylam Pharmaceuticals | $401.80
+2.4% | 2/26/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $300.00 -> $300.00 | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/26/2025 |
MGTX MeiraGTx | $7.65
| 2/24/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $36.00 -> $36.00 | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 2/24/2025 |
PRTA Prothena | $6.81
-0.9% | 2/21/2025 | R. Li | Reiterated Rating | Buy -> Buy | $40.00 -> $40.00 | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 2/21/2025 |
KRYS Krystal Biotech | $156.98
+2.0% | 2/20/2025 | Geulah Livshits | Boost Price Target | Buy -> Buy | $212.00 -> $218.00 | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 2/20/2025 |
SLDB Solid Biosciences | $6.83
-0.1% | 2/19/2025 | Geulah Livshits | Boost Price Target | Buy -> Buy | $15.00 -> $16.00 | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 2/19/2025 |
STOK Stoke Therapeutics | $12.91
+0.5% | 2/19/2025 | R. Li | Reiterated Rating | Buy -> Buy | $24.00 -> $24.00 | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 2/19/2025 |
OTLK Oncobiologics | $1.93
-1.5% | 2/18/2025 | D. Gataulin | Reiterated Rating | Neutral -> Neutral | $3.00 -> $3.00 | View details for Chardan Capital rating of Oncobiologics (NASDAQ:OTLK) on 2/18/2025 |
The Coin That Could Define Trump’s Crypto Presidency (Ad) When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed.
While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.” Discover the coin that could define Trump’s crypto presidency. |
OCGN Ocugen | $0.99
-3.5% | 2/13/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 2/13/2025 |
CRSP CRISPR Therapeutics | $56.09
-0.3% | 2/13/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $94.00 -> $84.00 | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/13/2025 |
ARWR Arrowhead Pharmaceuticals | $15.93
+0.8% | 2/11/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $60.00 -> $60.00 | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/11/2025 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 2/11/2025 | Geulah Livshits | Lower Price Target | Buy -> Buy | $39.00 -> $30.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 2/11/2025 |
COYA Coya Therapeutics | $6.09
+2.4% | 2/6/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 2/6/2025 |
EYPT EYEPOINT PHARMACEUTICALS | $9.71
-1.1% | 2/6/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $33.00 -> $33.00 | View details for Chardan Capital rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 2/6/2025 |
CRGX CARGO Therapeutics | $4.49
+0.4% | 1/30/2025 | Geulah Livshits | Downgrade | Buy -> Neutral | | View details for Chardan Capital rating of CARGO Therapeutics (NASDAQ:CRGX) on 1/30/2025 |
SABS SAB Biotherapeutics | $2.23
+18.6% | 1/29/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 1/29/2025 |
OCGN Ocugen | $0.99
-3.5% | 1/23/2025 | Daniil Gataulin | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 1/23/2025 |
DYN Dyne Therapeutics | $10.05
+2.0% | 1/10/2025 | Keay Nakae | Reiterated Rating | Buy -> Buy | $50.00 -> $50.00 | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 1/10/2025 |
IMRX Immuneering | $3.37
-2.0% | 1/8/2025 | - | Reiterated Rating | Buy -> Buy | $13.00 -> $13.00 | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 1/8/2025 |
OCS Oculis | $17.70
+0.3% | 1/7/2025 | - | Reiterated Rating | Buy -> Buy | $28.00 -> $28.00 | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 1/7/2025 |
STOK Stoke Therapeutics | $12.91
+0.5% | 12/20/2024 | R. Li | Initiated Coverage | Buy | $24.00 | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 12/20/2024 |
PRTA Prothena | $6.81
-0.9% | 12/20/2024 | R. Li | Initiated Coverage | Buy | $40.00 | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 12/20/2024 |
MNMD Mind Medicine (MindMed) | $8.44
-7.2% | 12/20/2024 | R. Li | Initiated Coverage | Buy | $20.00 | View details for Chardan Capital rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 12/20/2024 |
CGTX Cognition Therapeutics | $0.67
+13.9% | 12/19/2024 | - | Reiterated Rating | Buy -> Buy | $11.00 -> $11.00 | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 12/19/2024 |
KRYS Krystal Biotech | $156.98
+2.0% | 12/18/2024 | - | Reiterated Rating | Buy -> Buy | $212.00 -> $212.00 | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 12/18/2024 |
TNYA Tenaya Therapeutics | $0.67
-0.8% | 12/18/2024 | - | Reiterated Rating | Buy -> Buy | $18.00 -> $18.00 | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 12/18/2024 |
INOD Innodata | $44.96
-18.1% | 12/13/2024 | - | Reiterated Rating | Buy | $45.00 | View details for Chardan Capital rating of Innodata (NASDAQ:INOD) on 12/13/2024 |
EDIT Editas Medicine | $2.44
-2.8% | 12/13/2024 | Y. Livshits | Reiterated Rating | Buy -> Neutral | | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 12/13/2024 |
KRYS Krystal Biotech | $156.98
+2.0% | 12/12/2024 | - | Reiterated Rating | Buy -> Buy | $212.00 -> $212.00 | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 12/12/2024 |
ARWR Arrowhead Pharmaceuticals | $15.93
+0.8% | 12/12/2024 | - | Reiterated Rating | Buy -> Buy | $60.00 -> $60.00 | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 12/12/2024 |
PRQR ProQR Therapeutics | $2.08
-1.0% | 12/12/2024 | - | Reiterated Rating | Buy -> Buy | $4.00 -> $4.00 | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 12/12/2024 |
CRVO CervoMed | $8.83
+7.0% | 12/11/2024 | D. Gataulin | Reiterated Rating | Buy -> Neutral | | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 12/11/2024 |
CRSP CRISPR Therapeutics | $56.09
-0.3% | 12/10/2024 | - | Reiterated Rating | Buy -> Buy | $94.00 -> $94.00 | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 12/10/2024 |
FBRX Forte Biosciences | $9.61
-3.7% | 12/4/2024 | - | Reiterated Rating | Buy -> Buy | $64.00 -> $64.00 | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 12/4/2024 |
SNTI Senti Biosciences | $1.68
-1.2% | 12/2/2024 | - | Reiterated Rating | Buy -> Buy | $10.00 -> $10.00 | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 12/2/2024 |
OTLK Oncobiologics | $1.93
-1.5% | 12/2/2024 | D. Gataulin | Reiterated Rating | Buy -> Neutral | | View details for Chardan Capital rating of Oncobiologics (NASDAQ:OTLK) on 12/2/2024 |
ARWR Arrowhead Pharmaceuticals | $15.93
+0.8% | 11/27/2024 | - | Reiterated Rating | Buy -> Buy | $60.00 -> $60.00 | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/27/2024 |
MGX Metagenomi | $2.25
-2.2% | 11/20/2024 | - | Reiterated Rating | Buy -> Buy | $15.00 -> $15.00 | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 11/20/2024 |
IMRX Immuneering | $3.37
-2.0% | 11/20/2024 | - | Reiterated Rating | Buy -> Buy | $13.00 -> $13.00 | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 11/20/2024 |
RGNX REGENXBIO | $8.19
-3.8% | 11/20/2024 | - | Reiterated Rating | Buy -> Buy | $52.00 -> $52.00 | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 11/20/2024 |
ABUS Arbutus Biopharma | $3.27
-0.3% | 11/20/2024 | - | Reiterated Rating | Buy -> Buy | $4.50 -> $5.00 | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 11/20/2024 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 11/18/2024 | - | Reiterated Rating | Buy -> Buy | $62.00 -> $62.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/18/2024 |
OCGN Ocugen | $0.99
-3.5% | 11/18/2024 | - | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 11/18/2024 |
MGTX MeiraGTx | $7.65
| 11/18/2024 | - | Reiterated Rating | Buy -> Buy | $36.00 -> $36.00 | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 11/18/2024 |
NTLA Intellia Therapeutics | $11.49
-1.3% | 11/18/2024 | - | Boost Price Target | Buy -> Buy | $88.00 -> $91.00 | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 11/18/2024 |
FBRX Forte Biosciences | $9.61
-3.7% | 11/15/2024 | - | Boost Price Target | Buy -> Buy | $3.00 -> $64.00 | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 11/15/2024 |
CGTX Cognition Therapeutics | $0.67
+13.9% | 11/15/2024 | D. Gataulin | Reiterated Rating | Buy -> Buy | $11.00 -> $11.00 | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 11/15/2024 |
CLSD Clearside Biomedical | $0.38
-7.8% | 11/15/2024 | D. Gataulin | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 11/15/2024 |
CRVO CervoMed | $8.83
+7.0% | 11/14/2024 | D. Gataulin | Reiterated Rating | Buy -> Buy | $55.00 -> $55.00 | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 11/14/2024 |
TSHA Taysha Gene Therapies | $2.63
-3.7% | 11/14/2024 | - | Reiterated Rating | Buy -> Buy | $7.00 -> $7.00 | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 11/14/2024 |
PASG Passage Bio | $5.74
-10.6% | 11/14/2024 | - | Reiterated Rating | Buy -> Buy | $140.00 -> $140.00 | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 11/14/2024 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 11/14/2024 | - | Reiterated Rating | Buy -> Buy | $39.00 -> $39.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 11/14/2024 |
ALUR Allurion Technologies | $2.76
-0.7% | 11/14/2024 | K. Nakae | Downgrade | Buy -> Neutral | | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 11/14/2024 |
MCRB Seres Therapeutics | $13.99
-1.9% | 11/13/2024 | - | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 11/13/2024 |
RNA Avidity Biosciences | $35.92
-2.2% | 11/13/2024 | K. Nakae | Reiterated Rating | Buy -> Buy | $65.00 -> $65.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 11/13/2024 |
DYN Dyne Therapeutics | $10.05
+2.0% | 11/13/2024 | - | Reiterated Rating | Buy -> Buy | $50.00 -> $50.00 | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 11/13/2024 |
OBIO Orchestra BioMed | $2.44
-20.3% | 11/13/2024 | - | Reiterated Rating | Buy -> Buy | $20.00 -> $20.00 | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 11/13/2024 |
PRME Prime Medicine | $4.04
+8.0% | 11/13/2024 | - | Lower Price Target | Buy -> Buy | $17.00 -> $15.00 | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 11/13/2024 |
The Coin That Could Define Trump’s Crypto Presidency (Ad) When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed.
While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.” Discover the coin that could define Trump’s crypto presidency. |
FEMY Femasys | $0.82
-1.2% | 11/13/2024 | - | Lower Price Target | Buy -> Buy | $10.00 -> $8.00 | View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 11/13/2024 |
CRGX CARGO Therapeutics | $4.49
+0.4% | 11/13/2024 | G. Livshits | Reiterated Rating | Buy -> Buy | $28.00 -> $28.00 | View details for Chardan Capital rating of CARGO Therapeutics (NASDAQ:CRGX) on 11/13/2024 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 11/13/2024 | - | Boost Price Target | Buy -> Buy | $23.00 -> $25.00 | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/13/2024 |
SLDB Solid Biosciences | $6.83
-0.1% | 11/11/2024 | - | Reiterated Rating | Buy -> Buy | $15.00 -> $15.00 | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 11/11/2024 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 11/11/2024 | - | Reiterated Rating | Buy -> Buy | $62.00 -> $62.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/11/2024 |
ZURA Zura Bio | $1.50
+7.1% | 11/8/2024 | - | Lower Price Target | Buy -> Buy | $14.00 -> $12.00 | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 11/8/2024 |
OCGN Ocugen | $0.99
-3.5% | 11/8/2024 | - | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 11/8/2024 |
EYPT EYEPOINT PHARMACEUTICALS | $9.71
-1.1% | 11/8/2024 | - | Boost Price Target | Buy -> Buy | $28.00 -> $33.00 | View details for Chardan Capital rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 11/8/2024 |
SABS SAB Biotherapeutics | $2.23
+18.6% | 11/7/2024 | - | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 11/7/2024 |
TNYA Tenaya Therapeutics | $0.67
-0.8% | 11/7/2024 | - | Lower Price Target | Buy -> Buy | $20.00 -> $18.00 | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/7/2024 |
COYA Coya Therapeutics | $6.09
+2.4% | 11/7/2024 | - | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 11/7/2024 |
IPSC Century Therapeutics | $0.53
-2.9% | 11/7/2024 | - | Lower Price Target | Buy -> Buy | $17.00 -> $11.00 | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 11/7/2024 |
ABUS Arbutus Biopharma | $3.27
-0.3% | 11/6/2024 | - | Boost Price Target | Buy -> Buy | $4.00 -> $4.50 | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 11/6/2024 |
EDIT Editas Medicine | $2.44
-2.8% | 11/5/2024 | - | Reiterated Rating | Buy -> Buy | $12.00 -> $12.00 | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 11/5/2024 |
ALNY Alnylam Pharmaceuticals | $401.80
+2.4% | 11/1/2024 | - | Reiterated Rating | Buy -> Buy | $300.00 -> $300.00 | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/1/2024 |
CGTX Cognition Therapeutics | $0.67
+13.9% | 10/31/2024 | D. Gataulin | Reiterated Rating | Buy -> Buy | $11.00 -> $11.00 | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 10/31/2024 |
COYA Coya Therapeutics | $6.09
+2.4% | 10/30/2024 | - | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 10/30/2024 |
RNA Avidity Biosciences | $35.92
-2.2% | 10/30/2024 | K. Nakae | Boost Price Target | Buy -> Buy | $60.00 -> $65.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 10/30/2024 |
EYPT EYEPOINT PHARMACEUTICALS | $9.71
-1.1% | 10/29/2024 | - | Reiterated Rating | Buy -> Buy | $28.00 -> $28.00 | View details for Chardan Capital rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 10/29/2024 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 10/25/2024 | - | Reiterated Rating | Buy -> Buy | $23.00 -> $23.00 | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 10/25/2024 |
NTLA Intellia Therapeutics | $11.49
-1.3% | 10/24/2024 | - | Lower Price Target | Buy -> Buy | $94.00 -> $88.00 | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 10/24/2024 |
EDIT Editas Medicine | $2.44
-2.8% | 10/22/2024 | - | Lower Price Target | Buy -> Buy | $20.00 -> $12.00 | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 10/22/2024 |
RGNX REGENXBIO | $8.19
-3.8% | 10/22/2024 | - | Reiterated Rating | Buy -> Buy | $52.00 -> $52.00 | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 10/22/2024 |
CLSD Clearside Biomedical | $0.38
-7.8% | 10/14/2024 | D. Gataulin | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 10/14/2024 |
ALNY Alnylam Pharmaceuticals | $401.80
+2.4% | 10/11/2024 | - | Reiterated Rating | Buy -> Buy | $300.00 -> $300.00 | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 10/11/2024 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 9/19/2024 | - | Boost Price Target | Buy -> Buy | $38.00 -> $39.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 9/19/2024 |
CRVO CervoMed | $8.83
+7.0% | 9/18/2024 | D. Gataulin | Initiated Coverage | Buy | $55.00 | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 9/18/2024 |
SABS SAB Biotherapeutics | $2.23
+18.6% | 9/9/2024 | - | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 9/9/2024 |
MGX Metagenomi | $2.25
-2.2% | 9/5/2024 | - | Reiterated Rating | Buy -> Buy | $15.00 -> $15.00 | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 9/5/2024 |
ALUR Allurion Technologies | $2.76
-0.7% | 8/22/2024 | - | Lower Price Target | Buy -> Buy | $125.00 -> $62.50 | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 8/22/2024 |
CLSD Clearside Biomedical | $0.38
-7.8% | 8/21/2024 | D. Gataulin | Initiated Coverage | Buy | $6.00 | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 8/21/2024 |
FBRX Forte Biosciences | $9.61
-3.7% | 8/19/2024 | - | Reiterated Rating | Buy -> Buy | $3.00 -> $3.00 | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 8/19/2024 |
MGX Metagenomi | $2.25
-2.2% | 8/19/2024 | - | Lower Price Target | Buy -> Buy | $17.00 -> $15.00 | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 8/19/2024 |
OTLK Oncobiologics | $1.93
-1.5% | 8/16/2024 | D. Gataulin | Reiterated Rating | Buy -> Buy | $53.00 -> $53.00 | View details for Chardan Capital rating of Oncobiologics (NASDAQ:OTLK) on 8/16/2024 |
FEMY Femasys | $0.82
-1.2% | 8/14/2024 | - | Lower Price Target | Buy -> Buy | $12.00 -> $10.00 | View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 8/14/2024 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 8/14/2024 | - | Reiterated Rating | Buy -> Buy | $23.00 -> $23.00 | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 8/14/2024 |
MCRB Seres Therapeutics | $13.99
-1.9% | 8/14/2024 | - | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 8/14/2024 |
TSHA Taysha Gene Therapies | $2.63
-3.7% | 8/13/2024 | - | Reiterated Rating | Buy -> Buy | $7.00 -> $7.00 | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 8/13/2024 |
SABS SAB Biotherapeutics | $2.23
+18.6% | 8/12/2024 | - | Reiterated Rating | Buy -> Buy | $25.00 -> $25.00 | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 8/12/2024 |
GANX Gain Therapeutics | $1.44
-1.4% | 8/9/2024 | - | Reiterated Rating | Buy -> Buy | $6.00 -> $6.00 | View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 8/9/2024 |
RNA Avidity Biosciences | $35.92
-2.2% | 8/9/2024 | - | Boost Price Target | Buy -> Buy | $45.00 -> $60.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 8/9/2024 |
IMRX Immuneering | $3.37
-2.0% | 8/7/2024 | - | Lower Price Target | Buy -> Buy | $16.00 -> $12.00 | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 8/7/2024 |
CRSP CRISPR Therapeutics | $56.09
-0.3% | 8/6/2024 | - | Lower Price Target | Buy -> Buy | $112.00 -> $94.00 | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/6/2024 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 8/6/2024 | - | Reiterated Rating | Buy -> Buy | $62.00 -> $62.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 8/6/2024 |
KRYS Krystal Biotech | $156.98
+2.0% | 8/5/2024 | - | Boost Price Target | Buy -> Buy | $153.00 -> $208.00 | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 8/5/2024 |
MGTX MeiraGTx | $7.65
| 7/31/2024 | - | Reiterated Rating | Buy -> Buy | $36.00 | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 7/31/2024 |
ADVM Adverum Biotechnologies | $2.32
-2.9% | 7/18/2024 | - | Boost Price Target | Buy -> Buy | $4.00 -> $40.00 | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 7/18/2024 |
ARWR Arrowhead Pharmaceuticals | $15.93
+0.8% | 7/17/2024 | - | Reiterated Rating | Buy -> Buy | $60.00 -> $60.00 | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 7/17/2024 |
FDMT 4D Molecular Therapeutics | $6.42
+42.7% | 7/17/2024 | - | Reiterated Rating | Buy -> Buy | $38.00 -> $38.00 | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 7/17/2024 |
LXEO Lexeo Therapeutics | $4.61
-2.5% | 7/15/2024 | - | Reiterated Rating | Buy -> Buy | $23.00 -> $23.00 | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 7/15/2024 |
CRGX CARGO Therapeutics | $4.49
+0.4% | 7/8/2024 | G. Livshits | Initiated Coverage | Buy | $28.00 | View details for Chardan Capital rating of CARGO Therapeutics (NASDAQ:CRGX) on 7/8/2024 |
RCKT Rocket Pharmaceuticals | $2.99
-2.0% | 6/28/2024 | - | Reiterated Rating | Buy -> Buy | $62.00 -> $62.00 | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 6/28/2024 |
EYPT EYEPOINT PHARMACEUTICALS | $9.71
-1.1% | 6/28/2024 | - | Reiterated Rating | Buy -> Buy | $28.00 -> $28.00 | View details for Chardan Capital rating of EYEPOINT PHARMACEUTICALS (NASDAQ:EYPT) on 6/28/2024 |
ARWR Arrowhead Pharmaceuticals | $15.93
+0.8% | 6/26/2024 | - | Reiterated Rating | Buy -> Buy | $60.00 -> $60.00 | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/26/2024 |
TSHA Taysha Gene Therapies | $2.63
-3.7% | 6/18/2024 | - | Reiterated Rating | Buy -> Buy | $7.00 -> $7.00 | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 6/18/2024 |
RNA Avidity Biosciences | $35.92
-2.2% | 6/12/2024 | - | Boost Price Target | Buy -> Buy | $33.00 -> $45.00 | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 6/12/2024 |
OBIO Orchestra BioMed | $2.44
-20.3% | 6/12/2024 | - | Reiterated Rating | Buy -> Buy | $20.00 -> $20.00 | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 6/12/2024 |
OCS Oculis | $17.70
+0.3% | 6/11/2024 | - | Reiterated Rating | Buy -> Buy | $30.00 -> $30.00 | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 6/11/2024 |
CGTX Cognition Therapeutics | $0.67
+13.9% | 6/6/2024 | D. Gataulin | Initiated Coverage | Buy | $11.00 | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 6/6/2024 |
COYA Coya Therapeutics | $6.09
+2.4% | 6/5/2024 | - | Reiterated Rating | Buy -> Buy | $14.00 -> $14.00 | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 6/5/2024 |
